U.S., May 15 -- ClinicalTrials.gov registry received information related to the study (NCT06971744) titled 'Autophagy Maintenance (AUTOMAIN)' on April 03.
Brief Summary: This is a single-institution, single-arm study with a safety lead-in to determine if previously established safe doses of autophagy drugs, hydroxychloroquine (HCQ) and nelfinavir mesylate (NFV) will benefit ovarian cancer patients in a maintenance setting. Patients will receive the two study drugs HCQ and NFV in combination with maintenance bevacizumab.
Study Start Date: June 01
Study Type: INTERVENTIONAL
Condition:
Ovarian Cancer
Intervention:
DRUG: Hydroxychloroquine
3 x 200 milligram tablets twice daily
DRUG: Nelfinavir
2x 625 milligram tablets twice daily
DRU...